
ÌLEGUKANNINGAR, SUM GEVA EINA GREIÐA SJÚKUGREINING
Amplexa Genetics bjóðar framkomnar arvafrøðiligar kanningar, ið hjálpa læknum at sjúkugreina vanligar sjúkur ímillum føroyingar.FØROYAKANNINGIN
Føroyakanningin ger greitt, um tú ert berari av eini ella fleiri av teim kendu sjúkuelvandi ílegubroytingunum, sum serstakliga javnan koma fyri í og hjá føroyingumSJÚKURNAR
Arvafrøðiligar kanningar kunnu greiða, um vit bera broytingar í okkara arvamassa. Sjúkuelvandi broytingarnar í arvamassanum er tað, vit kalla ílegu-úrbregði. Tað eru júst kanningar fyri 12 vanlig føroysk ílegu-úrbregði/sjúkur, vit í Amplexa Genetics nú bjóða einstaklingumCYSTISK FIBROSA
Ergrundað á broytingar í CFTR-íleguni. Cystisk Fibrosa (CF1) vísir seg óvanligaofta í Føroyum (hægsti berara-títtleiki í verðini). Tað er bert einiíleguvarianturin, ið sæst so ofta.Á Amplexa Genetics hava vit serkunleika innan mýla-
og arvafrøði, sum eru grundarlagið
undir persónlagari viðgerð
NÝGGJHEITIR
MOTHER'S DAY, 2022
When the decision to become a mother is carefully planned, it guarantees safety and stability for the future baby. Amplexa Genetics helps both doctors and future mothers by providing a genetic test for women who want the best start for their future child. We offer the X-linked Carrier test, a genetic screening test investigating 12 different genes associated with recessive diseases specifically associated with the X chromosome.Read more...
PURPLE DAY, 26 MARCH
Today, March 26th, is Purple Day, a day dedicated to raising epilepsy awareness worldwide. But at Amplexa, every day that we offer the best diagnosis in epilepsy is Purple Day.Epilepsy is among the most common chronic neurological diseases, with a prevalence of around 1% in the general population.
Read more...
RARE DISEASE DAY
Today, on Rare Disease Day, we get together to raise awareness of the challenges involved in living with a rare disease.At Amplexa we are passionate about raising community awareness through preventive actions. We make this possible with our gene panels: Genes2Life and Genes4Life.
Read more...